Cytokinetics CEO exercises options, sells 7,500 shares

CYTOKINETICS INC President & CEO Robert I. Blum exercised options for 7,500 shares of common stock at an exercise price of $10.60 per share and on the same date sold 7,500 shares at $76.76 per share, under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

CYTOKINETICS INC President & CEO Robert I. Blum exercised options for 7,500 shares of common stock at an exercise price of $10.60 per share and on the same date sold 7,500 shares at $76.76 per share, under a Rule 10b5-1 trading plan. Following the option exercise, he held 171,745 options directly, plus 2,083 shares of common stock in each of two irrevocable trusts reported as indirect ownership.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($496K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($576K)

Approx. gross sale proceeds $576K

Approx. exercise cost $80K

Approx. pre-tax spread $496K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.60	$80K
Sale	Common Stock	7,500	$76.76	$576K
holding	Common Stock F1	--	--	--
holding	Common Stock F2	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 171,745 contracts (Direct); Common Stock — 377,820 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1); Common Stock — 2,083 shares (Indirect, by Trust 2)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Options Exercised: 7,500 shares Exercise Price: $10.60 per share Shares Sold: 7,500 shares +4 more

7 metrics

Options Exercised 7,500 shares Non-Qualified Stock Option exercised on 2026-08-10

Exercise Price $10.60 per share Exercise price of Non-Qualified Stock Option

Shares Sold 7,500 shares Common stock sale on 2026-08-10

Sale Price $76.76 per share Price for common stock sale transaction

Options Remaining 171,745 options Total options following the option exercise

Trust 1 Holdings 2,083 shares Common stock held by The Bridget Blum 2003 Irrevocable Trust

Trust 2 Holdings 2,083 shares Common stock held by The Brittany Blum 2003 Irrevocable Trust

Key Terms

Non-Qualified Stock Option, Irrevocable Trust, indirect ownership

3 terms

Non-Qualified Stock Option financial

"security_title: Non-Qualified Stock Option (Right to Buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Irrevocable Trust financial

"Shares held by The Bridget Blum 2003 Irrevocable Trust."

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

indirect ownership financial

"ownership_type: indirect for trust-held common stock positions"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CYTK CEO Robert Blum report in this Form 4 transaction?

Robert Blum exercised 7,500 options at $10.60 and sold 7,500 shares at $76.76. The filing also shows remaining 171,745 options and indirect holdings in two irrevocable trusts.

How many CYTK shares did Robert Blum sell and at what price?

Robert Blum reported selling 7,500 shares of CYTOKINETICS INC common stock at $76.76 per share. This sale occurred on 2026-08-10 as part of a sequence tied to an option exercise.

What options did Robert Blum exercise in CYTK on this Form 4 date?

He exercised a Non-Qualified Stock Option for 7,500 shares of CYTOKINETICS INC common stock at an exercise price of $10.60 per share, originally granted with an expiration date of 2027-02-28.

How many CYTK options does Robert Blum hold after this transaction?

After the reported option exercise, Robert Blum directly held 171,745 non-qualified stock options. This figure reflects the total options following the transaction for the exercised grant listed in the Form 4 data.

What indirect CYTK shareholdings are reported for Robert Blum?

The Form 4 lists 2,083 shares of CYTOKINETICS INC common stock held by The Bridget Blum 2003 Irrevocable Trust and another 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both reported as indirect ownership.

Were Robert Blum’s CYTK trades made under a trading plan?

Yes, the Form 4 indicates the trades were made under a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to systematically trade shares according to preset instructions, independent of later material nonpublic information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 05:12 PM Accepted by SEC EDGAR 08/10/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		M		7,500	A	$10.6	385,320	D
Common Stock	08/10/2026		S		7,500	D	$76.76	377,820	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	08/10/2026		M			7,500	03/28/2017	02/28/2027	Common Stock	7,500	$0	171,745	D

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)